Roivant Sciences's Return on Invested Capital Insights
Portfolio Pulse from Benzinga Insights
Roivant Sciences (NASDAQ:ROIV) reported Q4 sales of $27.38 million, up 84.19% from Q3, but still posted an overall loss of $60.86 million. The company's Return on Invested Capital (ROIC) was -20.49%, suggesting ineffective capital allocation. However, it beat analyst predictions for Q4 earnings per share, reporting $-0.2/share against the predicted $-0.36/share.
June 29, 2023 | 2:45 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Roivant Sciences reported increased Q4 sales but an overall loss, with a negative ROIC suggesting ineffective capital allocation. However, it beat analyst EPS predictions.
Roivant Sciences reported a significant increase in sales, but still posted an overall loss, indicating that the company is not yet profitable. The negative ROIC suggests that the company is not effectively allocating its capital, which could impact its future growth and profitability. However, the fact that it beat analyst predictions for its Q4 earnings per share could have a positive impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100